Table of Contents Author Guidelines Submit a Manuscript
Stem Cells International
Volume 2017 (2017), Article ID 2352954, 11 pages
https://doi.org/10.1155/2017/2352954
Research Article

Safety and Tolerance of Donor-Derived Mesenchymal Stem Cells in Pediatric Living-Donor Liver Transplantation: The MYSTEP1 Study

1Pediatric Gastroenterology and Hepatology, University Hospital Tübingen, Hoppe-Seyler-Straße 1, 72076 Tübingen, Germany
2Department of Pediatric Hematology and Oncology, University Hospital Tübingen, Hoppe-Seyler-Straße 1, 72076 Tübingen, Germany
3Department of Surgery, University Medical Center Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany
4Department of General, Visceral and Transplant Surgery, University Hospital Tübingen, Hoppe-Seyler-Straße 1, 72076 Tübingen, Germany

Correspondence should be addressed to Ekkehard Sturm

Received 8 February 2017; Accepted 8 May 2017; Published 27 June 2017

Academic Editor: Jay L. Vivian

Copyright © 2017 Steffen Hartleif et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Dhawan, “Immunosuppression in pediatric liver transplantation: are little people different?” Liver Transplantation, vol. 17, Supplement 3, pp. S13–S19, 2011. View at Google Scholar
  2. M. Gurevich, V. Guy-Viterbo, M. Janssen et al., “Living donor liver transplantation in children: surgical and immunological results in 250 recipients at Universite Catholique de Louvain,” Annals of Surgery, vol. 262, no. 6, pp. 1141–1149, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Kelly, “Safety and efficacy of tacrolimus in pediatric liver recipients,” Pediatric Transplantation, vol. 15, no. 1, pp. 19–24, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. V. L. Ng, A. Fecteau, R. Shepherd et al., “Studies of pediatric liver transplantation Research G: outcomes of 5-year survivors of pediatric liver transplantation: report on 461 children from a North American multicenter registry,” Pediatrics, vol. 122, no. 6, pp. e1128–e1135, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. R. S. Venick, “What is the future of pediatric liver transplantation? Optimal management of long-term recipients,” Liver Transplantation, vol. 20, Supplement 2, pp. S19–S21, 2014. View at Google Scholar
  6. K. M. Campbell, N. Yazigi, F. C. Ryckman et al., “High prevalence of renal dysfunction in long-term survivors after pediatric liver transplantation,” The Journal of Pediatrics, vol. 148, no. 4, pp. 475–480, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Prinz, B. Harder, A. Königsrainer, S. Nadalin, A. Busch, and E. Sturm, “Fifty consecutive pediatric liver transplants without graft loss or mortality: postoperative complications ar dominated by calcineurin inhibitor-associated side-effects,” Pediatric Transplantation, vol. 17, p. 67, 2013. View at Google Scholar
  8. A. Jain, G. Mazariegos, R. Kashyap et al., “Comparative long-term evaluation of tacrolimus and cyclosporine in pediatric liver transplantation,” Transplantation, vol. 70, no. 4, pp. 617–625, 2000. View at Publisher · View at Google Scholar
  9. R. Scheenstra, P. M. Peeters, H. J. Verkade, and A. S. Gouw, “Graft fibrosis after pediatric liver transplantation: ten years of follow-up,” Hepatology, vol. 49, no. 3, pp. 880–886, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Markiewicz-Kijewska, P. Kalicinski, P. Kluge et al., “Antibody-mediated rejection in pediatric liver transplant recipients,” Annals of Transplantation, vol. 19, pp. 119–123, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Krampera, J. Galipeau, Y. Shi, K. Tarte, and L. Sensebe, “Immunological characterization of multipotent mesenchymal stromal cells—the International Society for Cellular Therapy (ISCT) working proposal,” Cytotherapy, vol. 15, no. 9, pp. 1054–1061, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Snykers, T. Henkens, E. De Rop et al., “Role of epigenetics in liver-specific gene transcription, hepatocyte differentiation and stem cell reprogrammation,” Journal of Hepatology, vol. 51, no. 1, pp. 187–211, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Luetzkendorf, K. Nerger, J. Hering et al., “Cryopreservation does not alter main characteristics of good manufacturing process-grade human multipotent mesenchymal stromal cells including immunomodulating potential and lack of malignant transformation,” Cytotherapy, vol. 17, no. 2, pp. 186–198, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Di Nicola, C. Carlo-Stella, M. Magni et al., “Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli,” Blood, vol. 99, no. 10, pp. 3838–3843, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. F. Gieseke, J. Bohringer, R. Bussolari, M. Dominici, R. Handgretinger, and I. Muller, “Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells,” Blood, vol. 116, no. 19, pp. 3770–3779, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. R. H. Lee, J. M. Yu, A. M. Foskett et al., “TSG-6 as a biomarker to predict efficacy of human mesenchymal stem/progenitor cells (hMSCs) in modulating sterile inflammation in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 47, pp. 16766–16771, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. He, S. Zhou, H. Liu et al., “Indoleamine 2,3-dioxgenase transfected mesenchymal stem cells induce kidney allograft tolerance by increasing the production and function of regulatory T cells,” Transplantation, vol. 99, no. 9, pp. 1829–1838, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. F. Casiraghi, N. Azzollini, P. Cassis et al., “Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells,” Journal of Immunology, vol. 181, no. 6, pp. 3933–3946, 2008. View at Publisher · View at Google Scholar
  19. E. Eggenhofer, F. C. Popp, M. Mendicino et al., “Heart grafts tolerized through third-party multipotent adult progenitor cells can be retransplanted to secondary hosts with no immunosuppression,” Stem Cells Translational Medicine, vol. 2, no. 8, pp. 595–606, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. N. Obermajer, F. C. Popp, Y. Soeder et al., “Conversion of Th17 into IL-17A(neg) regulatory T cells: a novel mechanism in prolonged allograft survival promoted by mesenchymal stem cell-supported minimized immunosuppressive therapy,” Journal of Immunology, vol. 193, no. 10, pp. 4988–4999, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Corcione, F. Benvenuto, E. Ferretti et al., “Human mesenchymal stem cells modulate B-cell functions,” Blood, vol. 107, no. 1, pp. 367–372, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. S. M. Melief, E. Schrama, M. H. Brugman et al., “Multipotent stromal cells induce human regulatory T cells through a novel pathway involving skewing of monocytes toward anti-inflammatory macrophages,” Stem Cells, vol. 31, no. 9, pp. 1980–1991, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. W. Ge, J. Jiang, M. L. Baroja et al., “Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance,” American Journal of Transplantation, vol. 9, no. 8, pp. 1760–1772, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. M. J. Hoogduijn, F. Popp, R. Verbeek et al., “The immunomodulatory properties of mesenchymal stem cells and their use for immunotherapy,” International Immunopharmacology, vol. 10, no. 12, pp. 1496–1500, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. F. C. Popp, E. Eggenhofer, P. Renner et al., “Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate,” Transplant Immunology, vol. 20, no. 1-2, pp. 55–60, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Le Blanc, F. Frassoni, L. Ball et al., “Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study,” Lancet, vol. 371, no. 9624, pp. 1579–1586, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Duijvestein, A. C. Vos, H. Roelofs et al., “Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn’s disease: results of a phase I study,” Gut, vol. 59, no. 12, pp. 1662–1669, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. N. Obermajer, F. C. Popp, C. L. Johnson, V. Benseler, and M. H. Dahlke, “Rationale and prospects of mesenchymal stem cell therapy for liver transplantation,” Current Opinion in Organ Transplantation, vol. 19, no. 1, pp. 60–64, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. N. Perico, F. Casiraghi, M. Introna et al., “Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility,” Clinical Journal of the American Society of Nephrology, vol. 6, no. 2, pp. 412–422, 2011. View at Google Scholar
  30. M. E. Reinders, J. W. de Fijter, H. Roelofs et al., “Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase I study,” Stem Cells Translational Medicine, vol. 2, no. 2, pp. 107–111, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Tan, W. Wu, X. Xu et al., “Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial,” JAMA, vol. 307, no. 11, pp. 1169–1177, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. G. H. Pan, Z. Chen, L. Xu et al., “Low-dose tacrolimus combined with donor-derived mesenchymal stem cells after renal transplantation: a prospective, non-randomized study,” Oncotarget, vol. 7, no. 11, pp. 12089–12101, 2016. View at Publisher · View at Google Scholar · View at Scopus
  33. Y. Peng, M. Ke, L. Xu et al., “Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study,” Transplantation, vol. 95, no. 1, pp. 161–168, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. O. Detry, M. Vandermeulen, M. H. Delbouille et al., “Infusion of third-party mesenchymal stromal cells after liver transplantation: a phase I clinical study,” Transplant International, vol. 28, p. 10, 2015. View at Google Scholar
  35. Y. Soeder, M. Loss, C. L. Johnson et al., “First-in-human case study: multipotent adult progenitor cells for immunomodulation after liver transplantation,” Stem Cells Translational Medicine, vol. 4, no. 8, pp. 899–904. View at Publisher · View at Google Scholar · View at Scopus
  36. D. A. Kelly, J. C. Bucuvalas, E. M. Alonso et al., “Long-term medical management of the pediatric patient after liver transplantation: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation,” Liver Transplantation, vol. 19, no. 8, pp. 798–825, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Nadalin, M. Bockhorn, M. Malago, C. Valentin-Gamazo, A. Frilling, and C. E. Broelsch, “Living donor liver transplantation,” HPB: The Official Journal of the International Hepato Pancreato Biliary Association (Oxford), vol. 8, no. 1, pp. 10–21, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Nadalin, I. Capobianco, I. Konigsrainer, B. Harder, and A. Konigsrainer, “Living liver donor: indications and technical aspects,” Chirurg, vol. 86, no. 6, pp. 609–622, 2015. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Omori, Y. Ishizaki, H. Sugo et al., “Direct measurement of hepatic blood flow during living donor liver transplantation in children,” Journal of Pediatric Surgery, vol. 45, no. 3, pp. 545–548, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Sainz-Barriga, K. Reyntjens, M. G. Costa et al., “Prospective evaluation of intraoperative hemodynamics in liver transplantation with whole, partial and DCD grafts,” American Journal of Transplantation, vol. 10, no. 8, pp. 1850–1860, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Dillmann, F. C. Popp, B. Fillenberg et al., “Treatment-emergent adverse events after infusion of adherent stem cells: the MiSOT-I score for solid organ transplantation,” Trials, vol. 13, p. 211, 2012. View at Google Scholar
  42. S. Hartleif, H. Baier, M. Boeckle et al., “Validation of a toxicity score to assess safety in cell-based immunomodulatory therapy in pediatric liver transplantation,” Transplant International, vol. 28, p. 361, 2015. View at Google Scholar
  43. A. Dezsofi, U. Baumann, A. Dhawan et al., “Liver biopsy in children: position paper of the ESPGHAN Hepatology committee,” Journal of Pediatric Gastroenterology and Nutrition, vol. 60, no. 3, pp. 408–420, 2015. View at Publisher · View at Google Scholar · View at Scopus
  44. C. Venturi, C. Sempoux, J. Bueno et al., “Novel histologic scoring system for long-term allograft fibrosis after liver transplantation in children,” American Journal of Transplantation, vol. 12, no. 11, pp. 2986–2996, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. F. Bohne, M. Martinez-Llordella, J. J. Lozano et al., “Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation,” The Journal of Clinical Investigation, vol. 122, no. 1, pp. 368–382, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. R. P. Meier, Y. D. Muller, P. Morel, C. Gonelle-Gispert, and L. H. Buhler, “Transplantation of mesenchymal stem cells for the treatment of liver diseases, is there enough evidence?” Stem Cell Research, vol. 11, no. 3, pp. 1348–1364, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. P. Rowart, P. Erpicum, O. Detry et al., “Mesenchymal stromal cell therapy in ischemia/reperfusion injury,” Journal of Immunology Research, vol. 2015, Article ID 602597, 8 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  48. I. Muller, S. Kordowich, C. Holzwarth et al., “Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation,” Blood Cells, Molecules & Diseases, vol. 40, no. 1, pp. 25–32, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. F. C. Popp, B. Fillenberg, E. Eggenhofer et al., “Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation—a phase I study (MISOT-I),” Journal of Translational Medicine, vol. 9, p. 124, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. H. U. Meier-Kriesche, S. Li, R. W. Gruessner et al., “Immunosuppression: evolution in practice and trends, 1994-2004,” American Journal of Transplantation, vol. 6, no. 5, Part 2, pp. 1111–1131, 2006. View at Publisher · View at Google Scholar · View at Scopus
  51. C. L. Johnson, Y. Soeder, and M. H. Dahlke, “Mesenchymal stromal cells for immunoregulation after liver transplantation: the scene in 2016,” Current Opinion in Organ Transplantation, vol. 21, no. 6, pp. 541–549, 2016. View at Publisher · View at Google Scholar · View at Scopus
  52. N. Perico, F. Casiraghi, E. Gotti et al., “Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation,” Transplant International, vol. 26, no. 9, pp. 867–878, 2013. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Streitz, T. Miloud, M. Kapinsky et al., “Standardization of whole blood immune phenotype monitoring for clinical trials: panels and methods from the ONE study,” Transplantation Research, vol. 2, no. 1, p. 17, 2013. View at Publisher · View at Google Scholar
  54. M. D. Griffin, A. E. Ryan, S. Alagesan, P. Lohan, O. Treacy, and T. Ritter, “Anti-donor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far?” Immunology and Cell Biology, vol. 91, no. 1, pp. 40–51, 2013. View at Google Scholar
  55. M. Seifert, M. Stolk, D. Polenz, and H. D. Volk, “Detrimental effects of rat mesenchymal stromal cell pre-treatment in a model of acute kidney rejection,” Frontiers in Immunology, vol. 3, p. 202, 2012. View at Publisher · View at Google Scholar · View at Scopus
  56. S. Alagesan and M. D. Griffin, “Autologous and allogeneic mesenchymal stem cells in organ transplantation: what do we know about their safety and efficacy?” Current Opinion in Organ Transplantation, vol. 19, no. 1, pp. 65–72, 2014. View at Publisher · View at Google Scholar · View at Scopus
  57. T. Makela, R. Takalo, O. Arvola et al., “Safety and biodistribution study of bone marrow-derived mesenchymal stromal cells and mononuclear cells and the impact of the administration route in an intact porcine model,” Cytotherapy, vol. 17, no. 4, pp. 392–402, 2015. View at Publisher · View at Google Scholar · View at Scopus
  58. E. Eggenhofer, V. Benseler, A. Kroemer et al., “Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion,” Frontiers in Immunology, vol. 3, p. 297, 2012. View at Publisher · View at Google Scholar · View at Scopus
  59. F. Buron, H. Perrin, C. Malcus et al., “Human mesenchymal stem cells and immunosuppressive drug interactions in allogeneic responses: an in vitro study using human cells,” Transplantation Proceedings, vol. 41, no. 8, pp. 3347–3352, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. M. J. Hoogduijn, M. J. Crop, S. S. Korevaar et al., “Susceptibility of human mesenchymal stem cells to tacrolimus, mycophenolic acid, and rapamycin,” Transplantation, vol. 86, no. 9, pp. 1283–1291, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. J. D. Crossin, D. Muradali, and S. R. Wilson, “US of liver transplants: normal and abnormal,” Radiographics, vol. 23, no. 5, pp. 1093–1114, 2003. View at Publisher · View at Google Scholar
  62. C. P. Mullan, B. Siewert, R. A. Kane, and R. G. Sheiman, “Can Doppler sonography discern between hemodynamically significant and insignificant portal vein stenosis after adult liver transplantation?” AJR. American Journal of Roentgenology, vol. 195, no. 6, pp. 1438–1443, 2010. View at Google Scholar
  63. L. H. Gu, H. Fang, F. H. Li et al., “Prediction of early hepatic artery thrombosis by intraoperative color Doppler ultrasound in pediatric segmental liver transplantation,” Clinical Transplantation, vol. 26, no. 4, pp. 571–576, 2012. View at Publisher · View at Google Scholar · View at Scopus
  64. L. H. Jamieson, B. Arys, G. Low, R. Bhargava, S. Kumbla, and J. L. Jaremko, “Doppler ultrasound velocities and resistive indexes immediately after pediatric liver transplantation: normal ranges and predictors of failure,” AJR. American Journal of Roentgenology, vol. 203, no. 1, pp. W110–W116, 2014. View at Google Scholar